Bajo M A, Selgas R, Miranda B, Fernandez-Zamorano A, Borrego F, Romero J R, Caparros G, Riñon C, Sanchez Sicilia L
Hospital La Paz, Madrid, Spain.
Adv Perit Dial. 1991;7:296-300.
Anemia of CRF has been corrected by use of H-R-EPO both in hemodialysis and CAPD patients. Long term response to subcutaneous EPO and its relationship with serum EPO levels remain to be established. Twenty-five CAPD patients treated with CAPD during 30 +/- 28 (mean +/- SD) months were included in this study. The follow-up period was 6-24 months. All patients have been on CAPD at least 6 months and their Hemoglobin (Hb) level was lower than 8.5 g/dl. Twelve patients received EPO by subcutaneous route, at doses of 20 u./Kg daily and 13 other patients at doses of 2000 units twice a week. Thereafter, these doses were adjusted to obtain a Hemoglobin level ranging 10.5-13 g/dl. In conclusion, our results suggest that the subcutaneous route for H-R-Erythropoietin can be considered as the best choice for CAPD patients. Low doses twice a week seem to improve anemia in 2 months. Later, dose adjustment should be done according to the patient's response. The improvement in nutritional status we observed suggests a new positive aspect for EPO therapy. Our data did not show changes in peritoneal function.
在血液透析和持续性非卧床腹膜透析（CAPD）患者中，使用促红细胞生成素（H-R-EPO）已纠正了慢性肾衰竭（CRF）导致的贫血。皮下注射促红细胞生成素的长期反应及其与血清促红细胞生成素水平的关系仍有待确定。本研究纳入了25例接受CAPD治疗30±28（均值±标准差）个月的患者。随访期为6至24个月。所有患者进行CAPD至少6个月，且其血红蛋白（Hb）水平低于8.5 g/dl。12例患者通过皮下途径接受促红细胞生成素治疗，剂量为每日20单位/千克，另外13例患者剂量为每周两次2000单位。此后，调整这些剂量以使血红蛋白水平维持在10.5至13 g/dl之间。总之，我们的结果表明，皮下途径注射H-R-促红细胞生成素可被视为CAPD患者的最佳选择。每周两次低剂量似乎在2个月内可改善贫血。之后，应根据患者反应进行剂量调整。我们观察到的营养状况改善提示了促红细胞生成素治疗的一个新的积极方面。我们的数据未显示腹膜功能有变化。
